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Abstract
The incidence of protein conformational disorders is a problem affecting the aging
population and is an increasing cost on the health system. These diseases involve the
breakdown of control mechanisms within and outside of cells leading to accumulation
of unfolded and misfolded proteins. The control of protein folding, both inside and
outside the cell, is important to maintain the integrity of all proteins. Dysfunctions in this
control may lead to the development of protein conformational disorders.

Intracellularly the mechanisms monitoring the correct translation, modification,
assembly and transport of synthesised proteins are very well studied. However, in the
harsh extracellular environment, mechanisms to control protein folding need further
investigation. Extracellular chaperones have recently been proposed as an important
part of extracellular quality control for protein folding.

The ubiquitous glycoprotein clusterin has been implicated in this extracellular quality
control mechanism. A primary aim of the work described in this thesis was to examine
the relationship between clusterin structure and function. This was done using three
different approaches; characterisation of mutant clusterin expressed in transfected
CHO

cells;

characterisation

of

enzymatically

deglycosylated

clusterin;

and

characterisation of bacterially expressed recombinant clusterin domains.

Initially a panel of mutants was designed to disrupt predicted features of the protein,
consisting of five point mutants and five truncation mutants. The clusterin molecules
were expressed in CHO cells and were proteolytically processed with two subunits and
appeared to be normally glycosylated. The mutant clusterin molecules appeared to be
chaperone-active to some degree also, evidenced by their copurification with non-

xiv
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specific media proteins. In a rolling culture proteins in the media would be exposed to
sheer stress and one of the actions of clusterin is to bind to exposed hydrophobicity on
stressed proteins. A decrease in the amount of contaminating proteins copurified with
clusterin when static cultures were used instead of rolling cultures supports this
argument.

In an effort to understand the importance of the glyscosylation of clusterin, the
conjugated sugars were enzymatically removed to determine their effects on clusterin
function. The success of the deglycosylation process was first verified using SDSPAGE and mass spectrometry. Structural features of the deglycosylated molecule
were tested, with no change seen in the secondary structure of the deglycosylated
protein compared to the native protein. A shift to slightly acidic pH produced no change
in secondary structure as assessed by circular dichroism spectroscopy. Exposed
hydrophobicity was seen to increase with the removal of the sugars but the Kd of the
interaction with bisANS was not significantly different. At slightly acidic pH both the
wild type and deglycosylated molecules exposed a greater amount of hydrophobicity to
solution.

Binding to the known clusterin ligand megalin was also tested with a similar binding
affinity seen for both molecules, however the removal of sugars increased the rate at
which the molecule bound to and dissociated from megalin. Binding of the
deglycosylated molecule to known native ligands (IgG and GST) and stressed protein
ligands (lysozyme and BSA) was not affected by the absence of sugar moieties. The
chaperone activity of the deglycosylated molecule was also not different to the wild
type molecule.

Following the determination that the sugars appeared to have little effect on the activity
of clusterin, a series of domains was cloned into bacterial expression vectors. Two
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domains (αN: D23-E112 and βC: R306-E449) were purified and their structure and
function was examined. In the presence of a polar solvent both domains exhibited
alpha helical secondary structure as expected based on amino acid analysis, though in
aqueous buffer the domains had very little or no significant structure. The domains
alone did not have any effect on the heat stressed precipitation of citrate synthase.
Neither domain alone bound to heat-stressed lysozyme, however the αN domain
bound to the native protein ligand IgG and this was enhanced at slightly acidic pH, as
seen with native clusterin. The αN domain also bound with high affinity to LRP
indicating that this domain of clusterin is likely to be involved in binding interactions of
the entire molecule. Interaction between the αN and βC domains was also observed
and further investigation is required to determine binding and chaperone activity of the
interacting domains.

Understanding the functional relationship between the structure and function of
clusterin is important in understanding the role of clusterin in protein folding control.
This knowledge may also be important in the development of novel treatments for the
prevention or slowing of protein conformational diseases. The work in this manuscript
showed that the deglycosylated form of clusterin is as potent a chaperone as the entire
clusterin molecule. This indicated that a bacterially expressed form of clusterin may be
used to further investigate the function of the molecule. Recombinant domains of
clusterin were also studied to localise the regions of the molecule important in clusterin
binding and chaperone function. Further investigation is needed, however the use of
bacterially expressed recombinant proteins allows the potential development of
recombinant chaperone-active clusterin which may ultimately be used as a therapeutic
for protein conformational diseases. This research has gone some way to showing the
best methods of characterising the structural relevance to the binding and chaperone
activity of clusterin, and to providing a knowledge base for future investigations.
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